Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Rami S. Komrokji, MD, Amy E. DeZern, MD MHS, Katrina Zell, MA, MS, Najla H. Al Ali, BDS, MSc, Christopher Estling, Cassie Zimmerman, MPH, Wesley Hand, Francis Brown, Nicole Rizzo, John Barnard, PhD, Gail J Roboz, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 909.

https://doi.org/10.1182/blood.V126.23.909.909

Published: 2015

Journal Articles

Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs)

Mikkael A. Sekeres, MD MS, Katrina Zell, MA, MS, John Barnard, PhD, Amy E. DeZern, MD MHS, David P. Steensma, MD, Cassie Zimmerman, MPH, Christopher Estling, MS, Wesley Hand, Gail J. Roboz, MD, Nicole Rizzo, Najla H. Al Ali, BDS, MSc, Alan F. List, MD, Guillermo Garcia-Manero, MD, Jaroslaw P. Maciejewski, MD PhD, Rami S. Komrokji, MD

Blood (2015) 126 (23): 1696.

https://doi.org/10.1182/blood.V126.23.1696.1696

Published: 2015

Journal Articles

Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC)

Rami S. Komrokji, MD, Amy E. DeZern, MD MHS, Katrina Zell, MA, MS, Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Christopher Estling, Cassie Zimmerman, MPH, Wesley Hand, Francis Brown, Nicole Rizzo, John Barnard, PhD, Gail J Roboz, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Alan F. List, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 1697.

https://doi.org/10.1182/blood.V126.23.1697.1697

Published: 2015

Journal Articles

A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

Aziz Nazha, MD, Rami S. Komrokji, MD, Guillermo Garcia-Manero, MD, John Barnard, PhD, Katrina Zell, MA, MS, Cassie Zimmerman, MPH, Najla H. Al Ali, BDS, MSc, Gail J Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Eric Padron, MD, Elias J. Jabbour, MD, Molly Dara Greenberg, BS, Alan F. List, MD, Hagop M. Kantarjian, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 2888.

https://doi.org/10.1182/blood.V126.23.2888.2888

Published: 2015

Journal Articles

The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)

Amer M. Zeidan, MBBS, MHS, Mikkael A. Sekeres, MD MS, Guillermo Garcia-Manero, MD, John Barnard, Najla H Al Ali, Cassie Zimmerman, MA, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Elias Jabbour, MD, Hagop Kantarjian, MD, Katrina Zell, Quiqing Wang, Steven D Gore, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD PhD, Alan F. List, MD, Rami S Komrokji, MD

Blood (2014) 124 (21): 1935.

https://doi.org/10.1182/blood.V124.21.1935.1935

Published: 2014

NARROW

Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs)

Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC)

A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)

Email alerts

ASH Publications

American Society of Hematology

Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs)

Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC)

A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only